Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (JAZZ), ACADIA Pharmaceuticals Inc (ACAD) and Theravance Biopharma (TBPH)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Jazz Pharmaceuticals (JAZZ), ACADIA Pharmaceuticals Inc (ACAD) and Theravance Biopharma (TBPH).

Jazz Pharmaceuticals (JAZZ)

Mizuho Securities analyst Irina Rivkind Koffler reiterated a Hold rating on Jazz Pharmaceuticals today and set a price target of $137. The company’s shares opened today at $137.91.

Rivkind Koffler noted:

“We reiterate our Neutral rating as our 2019 estimates already reflect the company’s outlook post-share buyback, and OpEx guidance implies higher longer-term investment than contemplated by our model.”

According to TipRanks.com, Koffler is a 4-star analyst with an average return of 7.7% and a 39.8% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Assertio Therapeutics Inc, and Eagle Pharmaceuticals Inc.

Jazz Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $178.25, representing a 29.3% upside. In a report released today, H.C. Wainwright also maintained a Hold rating on the stock with a $153 price target.

See today’s analyst top recommended stocks >>

ACADIA Pharmaceuticals Inc (ACAD)

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on ACADIA Pharmaceuticals Inc, with a price target of $42. The company’s shares opened today at $23.01.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.6% and a 50.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Scholar Rock Holding Corp.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ACADIA Pharmaceuticals Inc with a $38.25 average price target, representing a 66.2% upside. In a report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $30 price target.

Theravance Biopharma (TBPH)

Needham analyst Alan Carr maintained a Buy rating on Theravance Biopharma today and set a price target of $40. The company’s shares opened today at $24.78.

Carr noted:

“Theravance mgmt provided a corporate update in a 4Q18 call yesterday. Yupelri generated $3.3M revenues to Theravance under Mylan co- promotion agreement, driven mostly by stocking. Both ampreloxetine (TD-9855) Phase 3 trials are now enrolling Neurogenic Orthostatic Hypotension patients. Mgmt reported long-term Phase 2 efficacy data are encouraging and will be presented mid-2019. Disease trial is underway and sites are being opened in Colitis trial. Phase 1 TD-8236 inhaled JAK inhibitor trial expected to be completed mid-2019. Phase 3 Trelegy CAPTAIN results in Asthma expected 1H19 (collaborator GSK), although we note substantial portion of royalty recently monetized. Reiterate BUY.”

According to TipRanks.com, Carr is a 4-star analyst with an average return of 3.0% and a 42.5% success rate. Carr covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Lexicon Pharmaceuticals.

Currently, the analyst consensus on Theravance Biopharma is a Moderate Buy with an average price target of $55, representing a 122.0% upside. In a report issued on February 20, Cantor Fitzgerald also maintained a Buy rating on the stock with a $55 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts